Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Annual Meeting, held December 6-9, 2025, in Orlando, Florida, showcased groundbreaking clinical advances in multiple myeloma ...

The complete response or better rate was 81.1% with the combination versus 31.1% in the control arm, while patients treated ...

In this installment of The OncoloGIST, Hans Lee, MD, director of Myeloma Research at Sarah Cannon Research Institute, ...

The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer ...

Legend Biotech Corp (NASDAQ:LEGN) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...